Our current study pinpointed SETD8 as the bona fide lysine methyltransferase of MYC at K412 in BC cells through mass spectrometry assay, co‐transfection assays in cells, in vitro methylation assays, gene‐edited knock‐in cell lines and SETD8 specific inhibitor treatment. This evidence concerns the gene KMT5A and breast cancer.